Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.

We examined phosphorothioate oligodeoxyribonucleotides (ODNs) directed against bcr in exon 3 or exon 2, which are rearranged with exon 2 of abl (B3A2 and B2A2) at t(9;22) of chronic myelogenous leukemia (CML). Since these ODNs are designed to be CML cell specific, we studied their effects on the human CML cell line K562, which is known to have B3A2 rearrangement, and leukemic cells from patients, as well as normal hematopoietic stem cells in vitro. In vitro experiments were performed to determine a potential role of these two ODNs as ex vivo purging agents. Incubation of B3A2 antisense at 40, 80, and 120 micrograms/ml with K562 CML cells for 72 hours at 37 degrees C resulted in 44%, 56%, and 63% reduction of CFU-L as compared to controls. In contrast, B3A2 sense and B2A2 antisense had no significant growth inhibitory effect on K562 cells. Incubation of B3A2 and B2A2 antisense ODNs at concentration of 80 micrograms/ml at 37 degrees C for 36 hours with normal peripheral blood stem/progenitor cells (PBSC) resulted in 124% and 98% CFU-GM formation as compared to untreated controls, respectively. However, incubation of PBSC with B3A2 and B2A2 sense-ODNs resulted in a 22% and 44% reduction in CFU-GM, respectively. In order to determine the ex vivo purging effects of bcr-abl ODNs, the K562 cells were mixed with PBSC from normal donors at a ratio of 1:20 (CML:PBSC). The mixture of cells was then incubated with B3A2 antisense at 80 micrograms/ml for 36 hrs at 37 degrees C. After incubation, no CML cells were detected by fluorescence in situ hybridization (FISH) as compared to untreated controls. These results were confirmed by RT-PCR using bcr-abl primers and mRNA isolated from the mixture of cells. Further, these results support the hypothesis that bcr-abl antisense ODNs are potentially effective agents for ex vivo purging of autologous stem cells before transplantation to eliminate/reduce the burden of leukemic cells. No significant toxicity to normal hematopoietic stem/progenitor cell population by the bcr-abl antisense ODNs was observed. Although unanticipated reductions in normal hematopoietic progenitor cells (CFU-GM) were observed with sense ODNs, no reduction in CFU-GM was observed with unrelated phosphorothioate ODN controls.

[1]  P. Iversen,et al.  Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Chase,et al.  Lack of reciprocal translocation in BCR-ABL positive Ph-negative chronic myeloid leukaemia. , 1994, Leukemia.

[3]  J. Stone,et al.  Identification of masked and variant Ph (complex type) translocations in CML and classic Ph in AML and ALL by fluorescence in situ hybridization with the use of bcr/abl cosmid probes. , 1993, Cancer genetics and cytogenetics.

[4]  K. Smetana,et al.  Nucleolar and nuclear aberrations in human lox tumor cells following treatment with p120 antisense oligonucleotide ISIS-3466. , 1993, Cancer letters.

[5]  E. Dennis,et al.  Antisense inhibition of group II phospholipase A2 expression blocks the production of prostaglandin E2 by P388D1 cells. , 1993, The Journal of biological chemistry.

[6]  J. Goldman,et al.  Autografting for patients with chronic myeloid leukemia—the hammersmith experience , 1993, Stem cells.

[7]  G. Gahrton,et al.  Intensive treatment in order to minimize the ph‐positive clone in chronic myelogenic leukemia , 1993, Stem cells.

[8]  D. Burns,et al.  Protein kinase C isotypes in human erythroleukemia (K562) cell proliferation and differentiation. Evidence that beta II protein kinase C is required for proliferation. , 1993, The Journal of biological chemistry.

[9]  J. Ávila,et al.  Depletion of casein kinase II by antisense oligonucleotide prevents neuritogenesis in neuroblastoma cells. , 1993, The EMBO journal.

[10]  G. Zon,et al.  In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Lion,et al.  Parental origin of chromosomes involved in the translocation t(9;22) , 1992, Nature.

[12]  R. Crooke,et al.  In vitro toxicological evaluation of ISIS 1082, a phosphorothioate oligonucleotide inhibitor of herpes simplex virus , 1992, Antimicrobial Agents and Chemotherapy.

[13]  J. Toulmé,et al.  Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[14]  B. Calabretta,et al.  Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. , 1991, Science.

[15]  B. Calabretta,et al.  Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[17]  A. Ho,et al.  Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. , 1990, Experimental hematology.

[18]  O. Witte,et al.  In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[20]  G. Daley,et al.  The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. , 1986, Science.

[21]  B. Dörken,et al.  Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. , 1986, Blood.

[22]  Kees Stam,et al.  Structural organization of the bcr gene and its role in the Ph′ translocation , 1985, Nature.

[23]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[24]  R. Zittoun,et al.  In vitro culture of clonogenic leukaemic cells in acute myeloid leukaemia: growth pattern and drug sensitivity , 1983, British journal of haematology.

[25]  A. Gewirtz.  Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia. , 1993, Leukemia & lymphoma.

[26]  J. Goldman,et al.  Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. , 1993, Leukemia & lymphoma.

[27]  F. Mandelli,et al.  What does one do for the CML patient in relapse after allogeneic bone marrow transplantation? , 1993, Leukemia & lymphoma.

[28]  K. Mills.  The relationship between the location of the breakpoint within the M-bcr and clinical parameters. , 1993, Leukemia & lymphoma.

[29]  L. Neckers,et al.  In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide. , 1991, Antisense research and development.

[30]  B. Calabretta,et al.  Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. , 1991, Folia histochemica et cytobiologica.

[31]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .